Cleo Diagnostics Selects Bio-Techne’s US Laboratory for Pivotal Ovarian Cancer Test Validation

smallcaps.com.au · 2026-09-10

Cleo Diagnostics taps Bio-Techne's US lab for pivotal validation of its pre-surgical ovarian cancer test ahead of a 510(k) FDA filing in H1 2027.

TickrTrends take: Bio-Techne's selection as the validation partner for Cleo Diagnostics' ovarian cancer diagnostic represents potential revenue expansion through strategic partnerships in the oncology diagnostics space. Given TickrTrends' current undervalued assessment of TECH, investors should monitor whether this collaboration translates into meaningful revenue contributions or licensing arrangements in upcoming earnings reports. The healthcare diagnostics sector has shown growing demand for early cancer detection platforms, making partnership wins a relevant metric for evaluating the company's growth trajectory relative to its current valuation.

Read the full story at smallcaps.com.au →